Kiniksa Pharmaceuticals: $35.8M Assets vs $41.9M Liabilities in 2024
Ticker: KNSA · Form: 10-K · Filed: Feb 25, 2025 · CIK: 1730430
| Field | Detail |
|---|---|
| Company | Kiniksa Pharmaceuticals International, PLC (KNSA) |
| Form Type | 10-K |
| Filed Date | Feb 25, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: financials, balance-sheet, pharmaceuticals
TL;DR
Kiniksa ended 2024 with more liabilities ($41.9M) than assets ($35.8M).
AI Summary
Kiniksa Pharmaceuticals International, plc filed its 2024 10-K on February 25, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, operating in the pharmaceutical preparations sector, had total assets of $35.8 million and total liabilities of $41.9 million as of December 31, 2024. This indicates a net liability position for the company at year-end.
Why It Matters
This filing provides a snapshot of Kiniksa Pharmaceuticals' financial health, showing a net liability position which could impact its ability to fund operations or future growth.
Risk Assessment
Risk Level: medium — The company has more liabilities than assets, which could indicate financial strain or a need for additional financing.
Key Numbers
- $35.8M — Total Assets (As of December 31, 2024)
- $41.9M — Total Liabilities (As of December 31, 2024)
- 2024-12-31 — Fiscal Year End (Reporting period)
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end date
- 2025-02-25 (date) — Filing date
- $35.8 million (dollar_amount) — Total assets as of December 31, 2024
- $41.9 million (dollar_amount) — Total liabilities as of December 31, 2024
FAQ
What were Kiniksa Pharmaceuticals' total assets and liabilities as of December 31, 2024?
As of December 31, 2024, Kiniksa Pharmaceuticals reported total assets of $35,781,373 and total liabilities of $41,881,319.
When did Kiniksa Pharmaceuticals file its 2024 10-K report?
Kiniksa Pharmaceuticals filed its 2024 10-K report on February 25, 2025.
What is the Standard Industrial Classification (SIC) code for Kiniksa Pharmaceuticals?
The SIC code for Kiniksa Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
What was the retained earnings balance for Kiniksa Pharmaceuticals at the end of fiscal year 2024?
The filing indicates a retained earnings balance for 2024-12-31, but the specific dollar amount is not provided in the excerpt.
What is the company's former name and when was the name change effective?
The company's former name was Kiniksa Pharmaceuticals, Ltd., and the name change to Kiniksa Pharmaceuticals International, plc was effective on 2018-02-05.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 25, 2025 regarding Kiniksa Pharmaceuticals International, plc (KNSA).